Oct 14, 2015
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented an overview of its broad RNAi delivery platform at the Annual Meeting of the Oligonucleotide Therapeutics Society in Leiden, the Netherlands. Included in this presentation was data from a new program, ARC-LPA, which is designed to reduce production of apolipoprotein A [apo(a)], a key component of lipoprotein(a) [Lp(a)]. Lp(a) has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Using a new subcutaneous delivery construct that Arrowhead has developed, an initial lead compound has achieved up to 90% knockdown of apo(a) in mice.